| Name | Title | Contact Details |
|---|
Forus Health is a medical technology start up founded in 2010 by a group of engineers with the goal to eradicate avoidable blindness. Over the years Forus Health has designed and developed affordable technology solutions to increase access and affordability of eye care. Our first product 3nethra classic is a compact and portable non-mydriatic fundus camera used for capturing digital images of the posterior (retina) and anterior (cornea) segments of the eye. The device is used for identifying common eye problems such as diabetic retinopathy, glaucoma, ARMD, cataract etc. The device is also integrated to a cloud based telemedicine platform which enables remote diagnosis. There are 40 million people who are blind globally, and 15 million live in India. The high incidence of blindness in India is due to a combination of several issues, but mostly due to limited access to eye care facilities, high cost of treatment/surgery and lack of awareness. The objective of Forus Health is to use technology to increase access, bring down the cost of diagnosis(affordability) and raise awareness (the three As). The key to our solution is not just the technology, but the way in which we have designed the deployment of the product.
Great Lakes Health Plan (GLHP) has been offering health care services to members eligible for Medicaid in the State of Michigan since March 1996. Our service area covers members living in 23 counties, including: Allegan, Berrien, Branch, Cass, Calhoun,
Asset Health is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sleep is essential and Ebb Therapeutics is working tirelessly to provide a clinically-proven, FDA-cleared device for the treatment of insomnia that is safe and effective for use every night -- without side effects.
Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.